Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fusidic acid repurposing study for anti-Wolbachia treatment of onchocerciasis
PACTR202603539981597Phase 2Not yet recruiting
- Sponsor
- University of Buea
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fusidic acid in onchocerciasis (5 arms), sponsored by University of Buea. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
fusidic acid
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on PACTR202603539981597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202603539981597.